Aktolun, CUMALİ

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/7158
Name Variants
Aktolun, umali
Aktolun, Cumali
Aktolun, C.
Job Title
Email Address
cumali.aktolun@ieu.edu.tr
Main Affiliation
09.02. Internal Sciences
Status
Former Staff
Website
ORCID ID
https://orcid.org/0000-0002-6245-9349 View this author’s ORCID profile
Scopus Author ID
56356834500
Turkish CoHE Profile ID
F4A97F54BB156446
Google Scholar ID
WoS Researcher ID
K-8514-2018

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
1
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
1
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents

66

Citations

1626

h-index

18

Go to Scopus profile
Documents

68

Citations

1506

Go to WoS profile
Scholarly Output

3

Articles

1

Views / Downloads

10/30

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

156

Scopus Citation Count

189

Patents

0

Projects

0

WoS Citations per Publication

52.00

Scopus Citations per Publication

63.00

Open Access Source

2

Supervised Theses

0

JournalCount
European Journal of Nuclear Medıcıne And Molecular Imagıng2
Thyroıd1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

20193
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Correction
    Artificial Intelligence and Radiomics in Nuclear Medicine: Potentials and Challenges (vol 46, Pg 2731, 2019)
    (Springer, 2019-11-28) Aktolun, Cumali
    [Abstract Not Available]
  • Thumbnail Image
    Editorial
    Citation - WoS: 27
    Citation - Scopus: 35
    Artificial Intelligence and Radiomics in Nuclear Medicine: Potentials and Challenges
    (Springer, 2019-11-15) Aktolun, Cumali
    Artificial intelligence involves a wide range of smart techniques that are applicable to medical services including nuclear medicine. Recent advances in computer power, availability of accumulated digital archives containing large amount of patient images, and records bring new opportunities for the implementation of artificial techniques in nuclear medicine. As a subset of artificial intelligence, machine learning is an emerging tool that can possibly perform many clinical tasks. Nuclear medicine community needs to adapt to this fast approaching smart era, to exploit the opportunities and tackle the problems associated with artificial intelligence tools. It is aimed in this editorial to outline the opportunities and challenges of artificial intelligence applications in nuclear medicine.
  • Thumbnail Image
    Article
    Citation - WoS: 129
    Citation - Scopus: 154
    European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium
    (Mary Ann Liebert, Inc, 2019-01) Luster, Markus; Aktolun, Cumali; Amendoeira, Isabel; Barczynski, Marcin; Bible, Keith C.; Duntas, Leonidas H.; Elisei, Rossella
    Background: The American Thyroid Association (ATA) management guidelines for patients with thyroid nodules and differentiated thyroid cancer (DTC) are highly influential practice recommendations. The latest revision appeared in 2015 (ATA 2015). These guidelines were developed predominantly by North American experts. European experts frequently have different perspectives, given epidemiological, technological/methodological, practice organization, and medicolegal differences between the respective regions. Summary: Divergent viewpoints were the focus of an invited symposium organized by the European Association of Nuclear Medicine involving 17 European thyroidologists, four ATA Guidelines Taskforce members, and an audience of 200 international experts. The group discussed the preoperative assessment of thyroid nodules, surgery and the role of pathology, radioiodine (RAI) therapy (RAIT), the assessment of initial therapy and dynamic risk stratification, and the treatment of persistent disease, recurrences, and advanced thyroid cancer. The dialogue resulted in this position paper contrasting European and ATA 2015 perspectives on key issues. One difference pertains to the permissiveness of ATA 2015 regarding lobectomy for primary tumors <= 4 cm. European panelists cited preclusion of RAIT, potential need for completion thyroidectomy, frequent inability to avoid chronic thyroid hormone replacement, and limitations of supportive evidence as arguments against widely applying lobectomy. Significant divergence involved ATA 2015's guidance regarding RAIT. European panelists favored wider use of postoperative RAIT than does ATA 2015. Rationales included the modality's association with favorable patient outcomes and generally limited toxicity, and lack of high-quality evidence supporting withholding RAIT. Additionally, European panelists favored recombinant human thyrotropin (rhTSH) in more settings than does ATA 2015, citing avoidance of hypothyroid morbidity and quality-of-life impairment, without apparent sacrifice in oncologic outcomes. Based on clinical evidence plus theoretical advantages, European experts advocated dosimetric versus fixed-activity RAIT approaches for advanced DTC. European panelists noted that the ATA 2015 risk-stratification system requires information sometimes unavailable in everyday practice. ATA 2015 recommendations regarding RAI-refractory DTC should consider potential palliative benefits of RAIT in patients who also have RAI-susceptible lesions. Conclusions: European panelists suggested modifications to approximately one-third of ATA 2015 recommendations. Varying European and ATA 2015 perspectives can stimulate analysis and discussion of the literature and performance of primary research to resolve discrepant recommendations and potentially improve patient outcomes.